CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Operating activities
Net loss	$ (190,669)	$ (182,219)	$ (237,038)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,119	2,989	3,274
Share-based compensation	41,169	54,050	43,234
Inventory write-down	303	2,096	2,887
Excess tax benefits from share-based compensation	(21)	75	(282)
Non-cash revenue from collaboration arrangements	0	(8,000)	0
Other	182	(65)	0
Changes in operating assets and liabilities:
Accounts receivable	1,276	(1,633)	(90)
Receivables from collaborative arrangements	26,156	(33,392)	(906)
Receivable from Innoviva, Inc	0	0	14,635
Prepaid taxes	9,522	(12,764)	0
Other prepaid and current assets	2,710	963	(2,878)
Inventories	(3,182)	1,030	(6,628)
Other assets	184	(572)	(211)
Accounts payable	(16,436)	8,717	3,917
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	17,192	(1,039)	11,680
Deferred rent	(632)	(552)	376
Income taxes payable	0	0	0
Deferred revenue	448	295	(7,991)
Other long-term liabilities	9,690	1,164	866
Net cash used in operating activities	(98,989)	(168,857)	(175,155)
Investing activities
Changes in restricted cash	0	0	(833)
Purchases of property and equipment and capitalized software	(2,135)	(2,647)	(3,107)
Purchases of marketable securities	(237,567)	(73,011)	(168,893)
Maturities of marketable securities	91,467	186,697	65,564
Sale of short-term investments and marketable securities	0	0	878
Payments received on notes receivable, net of issuance	0	0	140
Net cash (used in) provided by investing activities	(148,235)	111,039	(106,251)
Financing activities
Proceeds from sale of ordinary share, net	253,028	79,017	0
Proceeds from issuance of 3.250% convertible senior notes, net	222,498	0	0
Proceeds from ESPP purchases	3,172	3,124	0
Proceeds from option exercise	4,378	0	0
Excess tax benefits from share-based compensation	21	(75)	282
Repurchase of shares to satisfy tax withholding	(3,871)	(756)	(178)
Cash and cash equivalents contributed from Innoviva, Inc. (Note 1)	0	0	277,541
Transfers from Innoviva, Inc.	0	0	92,976
Net cash provided by financing activities	479,226	81,310	370,621
Net increase in cash and cash equivalents	232,002	23,492	89,215
Cash and cash equivalents at beginning of period	112,707	89,215	0
Cash and cash equivalents at end of period	344,709	112,707	89,215
Supplemental disclosure of cash flow information
Cash paid for interest	0	0	0
Cash (received) paid for income taxes, net	(9,488)	13,389	4,550
Supplemental disclosure of non-cash information
Contribution of net assets, excluding cash and cash equivalents, from Innoviva, Inc. (Note 11)	$ 0	$ 0	$ 125,337